Evaluating the clinical utility of the Atopic Dermatitis Control Tool: measurement properties and agreement between patients’ responses and clinicians’ impressions of atopic dermatitis control
Eric L. Simpson(Oregon Health & Science University), Isabelle Guillemin, Peter Lio(Northwestern University), Laurent Eckert(Sanofi (France)), T. Michelle Brown(RTI Health Solutions), Jingdong Chao(AbbVie (United States)), Lauren Nelson(RTI Health Solutions), Abhijit Gadkari(Regeneron (United States)), Puneet Mahajan(Research Triangle Park Foundation), Sheri Fehnel(RTI Health Solutions), Benjamin Lockshin(Georgetown University), Michaela Nygårdas
Cited by 2
Related Papers
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2.1k
Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis
|New England Journal of Medicine|2014|1.4k
Guidelines of care for the management of atopic dermatitis
|Journal of the American Academy of Dermatology|2013|1.3k
Guidelines of care for the management of atopic dermatitis
|Journal of the American Academy of Dermatology|2014|1.2k
Guidelines of care for the management of atopic dermatitis
|Journal of the American Academy of Dermatology|2014|870